arrow
C

Christian Pilarsky

universitätsklinikum erlangen
H指数:69
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326

更正:Lan et al. CRISPR-Cas9 筛选鉴定了 DYRK1A 是胰腺癌放疗增敏的靶点。Cancers 2022, 14, 326

2025-09-300
OAAI
Applications of 3D models in cholangiocarcinoma

3D模型在胆管癌中的应用

2025-08-020
OA
Identification of Cancer Associated Fibroblasts Related Genes Signature to Facilitate Improved Prediction of Prognosis and Responses to Therapy in Patients with Pancreatic Cancer

鉴定与癌症相关成纤维细胞相关基因特征,以促进改善对胰腺癌患者预后及治疗反应的预测

2025-05-190
OA
Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways

Jorunnamycin A通过调节KRAS介导的存活途径诱导胰腺导管腺癌细胞,球体和患者来源的类器官凋亡

2025-04-030
OAAI
Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
2024-07-220
PRE
Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer

罗氟司特抑制STK11/LKB1缺陷型胰腺癌的肿瘤生长和迁移

2024-03-091
OAAI
N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for Immunotherapy
2023-03-0122
OAAI
Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma
2023-02-0315
OAAI
Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis

改进的代谢生物标志物签名的独立验证和测定标准化,以区分胰腺导管腺癌和慢性胰腺炎

2022-11-0120
OA